Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Recruiting
Phase 2
Interventional Study
Maturity Onset Diabetes of the Young
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 10 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- Mansa · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY).
The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastroin…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of MODY via genetic testing
* HgbA1c \>6.5%
Exclusion Criteria:
* History of anaphylaxis to GLP-1 receptor agonists
* Already taking GLP-1 receptor agonists
* on medications within the stimulant class
* have had bariatric surgery
* personal or family history of can…
Contacts